Zofran Lawsuit Continues to Gain Plaintiffs

The story is a pretty well-known one by now: Zofran was created in 1991 by medical manufacturing giant GlaxoSmithKline and grew to become one of the most popular drugs ever. The actual medication works by limiting the amount of serotonin that gets to the part of the human brain that triggers nausea and vomiting. Obviously this is the kind of thing that a pregnant mother would love. Unfortunately the FDA only permitted the use of Zofran to surgery and cancer patients—not pregnant women.  Additionally, reports now allege that GlaxoSmithKline knew the product could be potentially hazardous to pregnant mothers and could cause birth defects.  The reality is pregnant women did take the medication and sadly many birth defects occurred, including musculoskeletal abnormalities, club foot, cleft lip, cleft palate, jaundice and heart deficiencies. This has caused a number of Zofran lawsuit claims to be filed.

The Zofran Lawsuit continues to gain plaintiffs
The Zofran Lawsuit continues to gain plaintiffs

Similar charges were brought by the Department of Justice, in one of the largest alleged health care fraud in history, a case GlaxoSmithKline settled for $3 billion. What is more stunning is additional plaintiffs have come forward now claiming the company has hid evidence of Zofran’s alleged link to major birth defects for more than two decades.

If you are interested in the December 2014 study that showed the impact of the drug on young mothers from Dr. Gideon Korenin in the American Journal of Obstetrics and Gynecology you can find that here.

The U.S. Food and Drug Administration [FDA] issued their formal warnings and instructions on Zofran here.

When lawsuits are brought against a pharmaceutical manufacturer such as GlaxoSmithKline, they either end in a financial settlement for the plaintiff or the lawsuits go to trial.  Generally, zofran lawsuit claims are settled prior to a trial. Medical Claim Legal and its experts have assisted Zofran lawsuit plaintiffs in similar claims.